Cargando…

Sintilimab for the treatment of non-small cell lung cancer

Anti-programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immunotherapy has dramatically changed the therapeutic landscape of inoperable non-small cell lung cancer (NSCLC), and has been included in first-line treatments. Sintilimab is a domestic anti-PD-1 monoclonal antibody in China that has...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Lin, Lin, Weihao, Tan, Fengwei, Li, Ning, Xue, Qi, Gao, Shugeng, Gao, Yibo, He, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014583/ https://www.ncbi.nlm.nih.gov/pubmed/35436956 http://dx.doi.org/10.1186/s40364-022-00363-7

Ejemplares similares

Prognostic significance of eighth edition TNM stage criteria in combined small-cell lung cancer
por: Zhao, Ziran, et al.
Publicado: (2023)

Specific organ metastases and prognosis in lung adenocarcinoma
por: Zhao, Ziran, et al.
Publicado: (2023)

Comprehensive analysis of the immunological implication and prognostic value of CXCR4 in non-small cell lung cancer
por: Guo, Wei, et al.
Publicado: (2022)

The Deubiquitinase USP13 Maintains Cancer Cell Stemness by Promoting FASN Stability in Small Cell Lung Cancer
por: Wang, Juhong, et al.
Publicado: (2022)

Development and Validation of a Nomogram Prognostic Model for Resected Limited-Stage Small Cell Lung Cancer Patients
por: Zeng, Qingpeng, et al.
Publicado: (2021)

Plasma extracellular vesicle microRNA profiling and the identification of a diagnostic signature for stage I lung adenocarcinoma
por: Gao, Shugeng, et al.
Publicado: (2021)

Comprehensive Analysis of Ferroptosis Regulators in Lung Adenocarcinomas Identifies Prognostic and Immunotherapy-Related Biomarkers
por: Sun, Sijin, et al.
Publicado: (2021)

PD‐L1 and CD47 co‐expression predicts survival and enlightens future dual‐targeting immunotherapy in non‐small cell lung cancer
por: Yang, Zhenlin, et al.
Publicado: (2021)

Surgical Outcomes of Synchronous Multiple Primary Non-Small Cell Lung Cancers
por: Zhang, Zhirong, et al.
Publicado: (2016)

Concurrent sintilimab with sequential chemoradiotherapy for unresectable, stage III non-small cell lung cancer: a retrospective study
por: Tang, Shi, et al.
Publicado: (2023)

Comparison of surgical difficulty in patients with resectable non-small cell lung cancer under different neoadjuvant treatment modes: a retrospective cohort study
por: Zhang, Fan, et al.
Publicado: (2021)

Systemic immune‐inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected non‐small cell lung cancer
por: Guo, Wei, et al.
Publicado: (2019)

The role of maintenance therapy in the treatment of elderly non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials
por: Zhang, Liangzhe, et al.
Publicado: (2017)

Prognostic value of tumor-infiltrating lymphocytes in esophageal cancer: an updated meta-analysis of 30 studies with 5,122 patients
por: Gao, Yibo, et al.
Publicado: (2020)

Plasma metabolomics study in screening and differential diagnosis of multiple primary lung cancer
por: Liu, Zixu, et al.
Publicado: (2023)

Meta-analysis of the efficacy and safety of sintilimab for treating advanced non-small cell lung cancer
por: Xie, Jiejie, et al.
Publicado: (2022)

Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for stage I lung adenocarcinoma
por: Guo, Wei, et al.
Publicado: (2022)

Promising response to a PD-1 inhibitor (sintilimab) in non-small cell lung cancer: A case report
por: Zhang, Lin, et al.
Publicado: (2020)

Lobectomy vs. sublobectomy for stage I non-small-cell lung cancer: a meta-analysis
por: Lv, Fang, et al.
Publicado: (2021)

Development and validation of an immune‐related prognostic signature in lung adenocarcinoma
por: Sun, Sijin, et al.
Publicado: (2020)

Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected esophageal squamous cell carcinoma
por: Gao, Yibo, et al.
Publicado: (2019)

A retrospective cohort study of sintilimab and pembrolizumab as first-line treatments for advanced non-small cell lung cancer
por: Wu, Kai, et al.
Publicado: (2022)

Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell lung cancer in China
por: Liu, Huiqin, et al.
Publicado: (2022)

Monoacylglycerol Lipase Knockdown Inhibits Cell Proliferation and Metastasis in Lung Adenocarcinoma
por: Zhang, Hao, et al.
Publicado: (2020)

Uniportal versus multiportal thoracoscopic sleeve lobectomy for the surgical treatment of centrally located lung cancer: a single institution experience
por: Zhao, Jun, et al.
Publicado: (2020)

Influence of adjuvant chemotherapy on survival for patients with stage IB and IIA non‐small cell lung cancer
por: Zhang, Pei, et al.
Publicado: (2020)

Blind spot in lung cancer lymph node metastasis: Cross‐lobe peripheral lymph node metastasis in early stage patients
por: Li, Ning, et al.
Publicado: (2018)

Correction: Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell lung cancer in China
por: Liu, Huiqin, et al.
Publicado: (2023)

An immune-related lncRNA signature predicts prognosis and adjuvant chemotherapeutic response in patients with small-cell lung cancer
por: Zhang, Zhihui, et al.
Publicado: (2021)

Effect of Sintilimab combined with Chemotherapy on Tumor Markers and Immune Function of advanced non-small cell lung cancer
por: Liang, Xiaoyan, et al.
Publicado: (2021)

Radiotherapy improves the outcomes of immunotherapy with Sintilimab in non-small-cell lung cancer: A real-world analysis
por: Li, Shuling, et al.
Publicado: (2022)

Loss of SUSD2 expression correlates with poor prognosis in patients with surgically resected lung adenocarcinoma
por: Guo, Wei, et al.
Publicado: (2020)

Comprehensive analyses of N (6)‐methyladenosine‐related long noncoding RNA profiles with prognosis, chemotherapy response, and immune landscape in small cell lung cancer
por: Luo, Yuejun, et al.
Publicado: (2022)

Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy
por: Jia, Lin, et al.
Publicado: (2022)

The landscape of m(6)A regulators in small cell lung cancer: molecular characteristics, immuno-oncology features, and clinical relevance
por: Zhang, Chaoqi, et al.
Publicado: (2021)

Elevated Heterogeneous Nuclear Ribonucleoprotein C Expression Correlates With Poor Prognosis in Patients With Surgically Resected Lung Adenocarcinoma
por: Guo, Wei, et al.
Publicado: (2021)

Single‐cell RNA sequencing analysis reveals transcriptional heterogeneity of multiple primary lung cancer
por: Guo, Wei, et al.
Publicado: (2023)

Two vs three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small-cell lung cancer: neoSCORE trial
por: Shao, Miner, et al.
Publicado: (2023)

Liquid biopsy for esophageal cancer: Is detection of circulating cell‐free DNA as a biomarker feasible?
por: Yuan, Zuyang, et al.
Publicado: (2020)

Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: A case report
por: Li, Gang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_13nlgiopup3uo3gl714hdumscr